ATE364048T1 - Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität - Google Patents

Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität

Info

Publication number
ATE364048T1
ATE364048T1 AT04011673T AT04011673T ATE364048T1 AT E364048 T1 ATE364048 T1 AT E364048T1 AT 04011673 T AT04011673 T AT 04011673T AT 04011673 T AT04011673 T AT 04011673T AT E364048 T1 ATE364048 T1 AT E364048T1
Authority
AT
Austria
Prior art keywords
cea
peptides
carcinoembryonic antigen
antagonistic activity
tachykinin antagonistic
Prior art date
Application number
AT04011673T
Other languages
English (en)
Inventor
Jeffrey Schlom
Nee Barzaga Maria Elen Salazar
Sam Zaremba
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE364048T1 publication Critical patent/ATE364048T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46448—Cancer antigens from embryonic or fetal origin
    • A61K39/464482—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT04011673T 1997-10-10 1998-09-22 Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität ATE364048T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6158997P 1997-10-10 1997-10-10

Publications (1)

Publication Number Publication Date
ATE364048T1 true ATE364048T1 (de) 2007-06-15

Family

ID=22036775

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04011673T ATE364048T1 (de) 1997-10-10 1998-09-22 Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität
AT98948429T ATE267213T1 (de) 1997-10-10 1998-09-22 Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT98948429T ATE267213T1 (de) 1997-10-10 1998-09-22 Peptide, die agonisten oder antagonisten des karzinoembrionalen antigens (cea) sind

Country Status (11)

Country Link
EP (1) EP1017810B1 (de)
JP (1) JP4291508B2 (de)
AT (2) ATE364048T1 (de)
AU (1) AU745863B2 (de)
CA (1) CA2308127C (de)
CY (1) CY1107706T1 (de)
DE (2) DE69837896T2 (de)
DK (1) DK1447414T3 (de)
ES (2) ES2217585T3 (de)
PT (1) PT1447414E (de)
WO (1) WO1999019478A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923309D0 (en) * 1999-10-01 1999-12-08 Glaxo Group Ltd Assay
ES2447115T3 (es) * 1999-10-11 2014-03-11 Institut Pasteur Vectores para la preparación de composiciones inmunoterapéuticas
DK1227837T3 (da) 1999-10-22 2008-09-15 Aventis Pasteur Fremgangsmåde til introduktion og/eller fremskyndelse af et immunrespons på et tumorantigen
CA2416893A1 (en) * 2000-07-31 2002-02-07 Aventis Pasteur Limited Modified cea and uses thereof
AU2003203140A1 (en) * 2002-01-17 2003-07-30 Pharmexa A/S Immunogenic carcinoembryonic antigen (cea)
US6949629B2 (en) 2002-03-13 2005-09-27 Aspenbio, Inc. Methods for purifying selected CEA family member proteins
EP2301356A3 (de) * 2002-12-04 2012-05-30 Baylor Research Institute Schnelles Ein-Schritt-Verfahren zur Erzeugung eines Antigen-geladenen dendritischen Impfstoffs aus Vorläufern
CN102370974B (zh) * 2002-12-16 2014-09-17 全球免疫股份有限公司 用于免疫治疗的基于酵母的疫苗
US7457855B2 (en) 2004-04-30 2008-11-25 Aol Llc Network configuration management
EP3061462B1 (de) 2007-07-02 2019-02-27 Etubics Corporation Verfahren und zusammensetzungen zur erzeugung eines adenovirusvektors zur verwendung mit mehreren impfungen
WO2009015841A1 (en) 2007-07-27 2009-02-05 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
JP5792630B2 (ja) 2009-01-28 2015-10-14 エピミューン，インコーポレイティド Ｐａｎ−ｄｒ結合ポリペプチドおよびその使用
ES2660597T3 (es) 2009-04-17 2018-03-23 Globeimmune, Inc. Composiciones inmunoterápicas de combinación contra el cáncer y métodos
WO2014031178A1 (en) 2012-08-24 2014-02-27 Etubics Corporation Replication defective adenovirus vector in vaccination
KR102193635B1 (ko) 2015-01-09 2020-12-21 이투빅스 코포레이션 복합 면역요법을 위한 방법 및 조성물
WO2016112188A1 (en) 2015-01-09 2016-07-14 Etubics Corporation Methods and compositions for ebola virus vaccination
WO2016172249A1 (en) 2015-04-20 2016-10-27 Etubics Corporation Methods and compositions for combination immunotherapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3399943B2 (ja) * 1991-05-06 2003-04-28 アメリカ合衆国 癌胎児性抗原を発現する組換えウイルスとその使用方法
US6001349A (en) * 1995-02-22 1999-12-14 Therion Biologics Corporation Generation of human cytotoxic T-cells specific for carcinoma self-associated antigens and uses thereof

Also Published As

Publication number Publication date
DE69824023T2 (de) 2005-05-12
CA2308127C (en) 2011-03-22
AU745863B2 (en) 2002-04-11
JP2002500002A (ja) 2002-01-08
WO1999019478A1 (en) 1999-04-22
ES2286530T3 (es) 2007-12-01
EP1017810A1 (de) 2000-07-12
DK1447414T3 (da) 2007-09-10
ES2217585T3 (es) 2004-11-01
ATE267213T1 (de) 2004-06-15
CY1107706T1 (el) 2013-04-18
EP1017810B1 (de) 2004-05-19
JP4291508B2 (ja) 2009-07-08
DE69837896D1 (de) 2007-07-19
PT1447414E (pt) 2007-07-18
AU9500498A (en) 1999-05-03
DE69837896T2 (de) 2008-02-14
DE69824023D1 (de) 2004-06-24
CA2308127A1 (en) 1999-04-22

Similar Documents

Publication Publication Date Title
ATE364048T1 (de) Peptide von carcinoembryonischem antigen (cea) mit tachykinin-antagonistischer aktivität
DE69730038D1 (de) Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
EA199800946A1 (ru) Концентрированный препарат антител
TR200003843T2 (tr) HCV kaplama proteinlerinin parçacıkları: aşılama için kullanım
DK0662000T3 (da) Antigen-bærende mikropartikler og deres anvendelse til at inducere humorale eller cellulære responser
DE69533923D1 (de) Cytokinin-designiertes lerk-5
ATE188486T1 (de) Modifizierte polypeptide mit erhoehter biologischer aktivitaet
ATE259377T1 (de) An den zelloberflächenrezeptor hek bindendes cytokin
TR200000654T2 (tr) KAY-Yeni bir bağışıklık sistemi proteini.
IL142905A0 (en) Functional antagonists of hedgehog activity
DE3787002T2 (de) Synthetische Peptide, die zelluläre Immunität gegen den AIDS-Virus und dessen Proteine erzeugen.
PT883687E (pt) Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes
DE69942072D1 (de) Von der Telomerase abgeleitete antigene Peptide
ATE68960T1 (de) Shampoo-praeparate.
HUP0002831A3 (en) Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
EP0739350A4 (de) Fas-antigenbindender ligand
DE69938786D1 (de) Die verwendung von peptiden von il-2 und peptid-derivaten als therapeutische wirkstoffe
BG102362A (en) New derivatives of amino acids, their preparation and application
DE68903576D1 (de) Signalpeptide, die in hefe wirksam sind und ihre verwendung zur sekretorischen expression von heterologen proteinen.
ES2123973T3 (es) Afamina: una proteina similar a la seroalbumina humana.
DE69227898T2 (de) Rekombinante hybride porinepitope
DE69637078D1 (de) Polypeptid-fragmente die fähig sind mit dem antigen i/ii von streptococcus mutans zu konkurrieren
ATE344052T1 (de) Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
EP1447414A3 (de) Peptide von carcinoembryonischem Antigen (CEA) mit Tachykinin-antagonistischer Aktivität
SE8502540D0 (sv) Stable dentifrice containing dextranase

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1447414

Country of ref document: EP